Ignite Creation Date:
2024-05-06 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 2:27 PM
Study NCT ID:
NCT05286437
Status:
RECRUITING
Last Update Posted:
2024-03-05
First Post:
2022-03-09
Brief Title:
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
Sponsor:
National Cancer Centre Singapore
Organization:
National Cancer Centre Singapore
Study Overview
Official Title:
Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole in the Advanced Setting - a Phase II Study
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LaPemERLA
Brief Summary:
This is a phase II study testing the combination of pembrolizumab with lenvatinib a multi-kinase inhibitor that has activity against vascular endothelial growth factor receptors 1-3 VEGFR1-3 fibroblast growth factor receptors 1-4 FGFR1-4 ret protooncogene RET platelet-derived growth factor receptor-alpha PDGFR-alpha and KIT a stem cell factor receptor and letrozole a non-steroidal aromatase inhibitor in advanced hormone receptor HR positive human epidermal growth factor receptor 2 HER2 negative breast cancer BC that has progressed onafter standard endocrine therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None